A practical reference on chronic hepatitis B: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
==== De novo motif discovery ==== There are software programs which, given multiple input sequences, attempt to identify one or more candidate motifs. One example is the Multiple EM for Motif Elicitation (MEME) algorithm, which generates statistical information for each candidate. There are more than 100 publications detailing motif discovery algorithms; Weirauch et al. evaluated many related algorithms in a 2013 benchmark. The planted motif search is another motif discovery method that is based on combinatorial approach.
Nvidia revealed the GeForce GTX 1080, the world's first graphics card with DisplayPort 1.4 support on 6 May 2016. AMD followed with the Radeon RX 480 to support DisplayPort 1.3/1.4 on 29 June 2016. The Radeon RX 400 series will support DisplayPort 1.3 HBR and HDR10, dropping the DVI connector(s) in the reference board design. In February 2017, VESA and Qualcomm announced that DisplayPort Alt Mode video transport will be integrated into the Snapdragon 835 mobile chipset, which powers smartphones, VR/AR head-mounted displays, IP cameras, tablets and mobile PCs.
== See also == RO5166017 – TAAR1 partial or full agonist RO5203648 – TAAR1 partial agonist RO5256390 – TAAR1 partial or full agonist RO5263397 – TAAR1 partial agonist EPPTB – TAAR1 antagonist/inverse agonist
As well as alpha and beta chains present in hemoglobin, about 3% of adult hemoglobin is made of alpha and delta globin chains. Just as with beta thalassemia, mutations that affect the ability of this gene to produce delta chains can occur.
== Description == Lonicera japonica is a twining vine able to climb up to 10 m (33 ft) high or more in trees, with opposite, simple oval leaves 3–8 cm (1+1⁄4–3+1⁄4 in) long and 2–3 cm (3⁄4–1+1⁄4 in) broad. When its stems are young, they are slightly red in color and may be fuzzy. Older stems are brown with peeling bark, and are often hollow on the inside. The flowers are double-tongued, opening white and fading to yellow, and sweetly vanilla scented. The fruit, which is produced in fall, is a black spherical berry 3–4 mm (1⁄8–3⁄16 in) diameter containing a few seeds.
Sources: en.wikipedia.org
== Background == United States Forces – Iraq was the military component of the American and Iraqi bilateral relationship, responsible for defense and security cooperation. The U.S.–Iraq Strategic Framework Agreement reads:
51 articles on history of Chinese medicine; called "impressive and essential" for latest scholarship and trustworthy bibliographic sources. "(Review) H-Sci-Med-Tech, July 2023. McGrew, Roderick. Encyclopedia of Medical History (1985), brief history on pp. 56–59 Needham J (2000). Sivin N (ed.). Part VI: Medicine. Science and Civilisation in China. Vol. 6, Biology and Biological Technology. Cambridge University Press. ISBN 978-0-521-63262-1. OCLC 163502797. Palmer, James (13 June 2013), "Do Some Harm", Aeon Raphals, Lisa (Winter 2020), "Chinese Philosophy and Chinese Medicine", in Zalta, Edward N. (ed.), The Stanford Encyclopedia of Philosophy, Metaphysics Research Lab, Stanford University Shelton, Tamara Venit (2019). Herbs and Roots: A History of Chinese Doctors in the American Medical Marketplace. New Haven: Yale University Press. ISBN 978-0-300-24940-8. Unschuld, Paul (1986). Nan-Ching: The Classic of Difficult Issues. Berkeley: University of California Press. ISBN 978-0-520-05372-4. —— (1986a). Medicine in China: A History of Pharmaceutics. Berkeley: University of California Press. ISBN 978-0-520-05025-9. —— (2000). Medicine in China: Historical Artifacts and Images. Munich: Prestel. ISBN 978-3-7913-2149-3. —— (2018). Traditional Chinese Medicine: Heritage and Adaptation [Traditionelle chinesische Medizin (2013)]. Translated by Bridie J. Andrews. New York: Columbia University Press. ISBN 978-0-231-17500-5.
The diagnosis of polyneuropathy begins with a history (anamnesis) and physical examination to ascertain the pattern of the disease process (such as arms, legs, distal, proximal), if they fluctuate, and what deficits and pain are involved. If pain is a factor, determining where and how long it has been present is important; one also needs to know what disorders are present within the family and what diseases the person may have. Although diseases often are suggested by the physical examination and history alone, tests that may be employed include electrodiagnostic testing, serum protein electrophoresis, nerve conduction studies, urinalysis, serum creatine kinase (CK) and antibody testing; nerve biopsy is done sometimes. Other tests may be used, especially tests for specific disorders associated with polyneuropathies; quality measures have been developed to diagnose patients with distal symmetrical polyneuropathy (DSP).
== SV == sv – (s) Swedish language (ISO 639-1 code) SV (s) El Salvador (ISO 3166 digram) (p) Sportverein (German for "Sport Association", as in Hamburger SV and SV Werder Bremen) SVC – (i) Secondary Visual Cortex SvD – (p) Svenska Dagbladet (Swedish newspaper) SVD (i) Singular Value Decomposition Snaiperskaya Vintovka Dragunova (Снайперская винтовка Драгунова, Russian for "Dragunov Sniper Rifle") SVG – (i) Scalable Vector Graphics SVK – (s) Slovakia (ISO 3166 trigram) SVM (p) Stroboscopic effect Visibility Measure; a measure for assessing a type of temporal light artefacts (i) Support Vector Machine (artificial intelligence) SVN – (s) Slovenia (ISO 3166 and FIFA trigram) SVO – (i) subject–verb–object SVR – (i) Sluzhba Vneshney Razvedki (Служба Внешней Разведки, Russian for "Foreign Intelligence Service")
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.